Involvement of the NO/cGMP/KATP pathway in the antinociceptive effect of the new pyrazole 5-(1-(3-fluorophenyl)-1H-pyrazol-4-yl)-2H-tetrazole (LQFM-021)

• DOI: 10.1016/j.niox.2015.02.146
• Publication Date: 2015-03-06T05:51:32Z
• Authors: Iziara F. Florentino; Pablinny M. Galdino; Lanussy P. De Oli...; Daiany P.B. Silva; Francine Pazini; Frederico A. Vand...; Luciano M. Lião; Ricardo Menegatti; Elson A. Costa
• Keywords: Licking

The pyrazol compounds are known to possess antipyretic, analgesic and anti-inflammatory activities. This study was conducted investigate the peripheral antinociceptive effect of pyrazole compound 5-(1-(3-Fluorophenyl)-1H-pyrazol-4-yl)-2H-tetrazole (LQFM-021) involvement opioid receptors NO/cGMP/KATP pathway. oral treatments in mice with LQFM-021 (17, 75 or 300 mg/kg) decreased number writhing. In formalin test, at doses 15, 30 60 mg/kg reduced licking time both neurogenic inflammatory phases this test. treatment animals (30 did not have effects tail-flick hot plate tests. Furthermore, pre-treatment naloxone (3 i.p.), L-name (10 ODQ i.p.) glibenclamide antagonized addition, it also demonstrated that LQFM-021(15, compromise motor activity chimney Only highest dose used promoted changes open field test pentobarbital-induced sleep thus ruling out possible false positive on nociception Our data suggest antinociception were mediated through activation